Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy
February 22, 2018 at 10:33 AM EST
The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|